Zacks Investment Research·Sep 15, 2026
Here's Why PRA Group Stock Remains a Buy Despite Few RisksPRAA's strong collections, portfolio income and investments support growth, while high debt and competition pose risks.
ProAssurance faces a challenging outlook characterized by persistent top-line contraction, evidenced by a 2.0% revenue decline in 2026Q1, and significant underwriting volatility driven by long-tail medical professional liability risks. While the company mainta...
Price trend, volume and key moving averages
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q2 2026Latest May 5, 2026 | $0.25+0.0% vs $0.25 | $224M+3.1% vs $217M |
Q1 2026 Feb 23, 2026 | $0.82+272.7% vs $0.22 | $232M+0.6% vs $231M |
Q4 2025 Nov 4, 2025 | $0.15-46.4% vs $0.28 | $275M+5.3% vs $261M |
Q3 2025 Aug 5, 2025 | $0.52+173.7% vs $0.19 | $277M+4.1% vs $266M |
PRAA's strong collections, portfolio income and investments support growth, while high debt and competition pose risks.
NAPA, Calif., June 26, 2026 /PRNewswire/ -- The Doctors Company, the nation's largest physician-owned medical malpractice insurer, announced today that it has completed the acquisition of ProAssurance Corporation (NYSE: PRA), a specialty insurer with broad expertise in medical liability, products liability for medical technology and life sciences companies, and workers' compensation insurance.
Benchmark PRA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for ProAssurance Corporation (PRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.00 | $1.29B | 25.25 | -2.67% | 4.64% | 3.99% | — | |
| $180.22 | $2.3B | 7.25 | 20.21% | 32.6% | 28.69% | — | |
| $131.54 | $3.49B | 18.35 | 58.16% | 18.61% | 21.61% | — | |
| $94.95 | $33.17B | 8.17 | 14.27% | 24.44% | 19.52% | — | |
| $58.13 | $5.33B | 13.33 | 6.33% | 22.22% | 24.37% | — | |
| $174.06 | $85.27B | 21.28 | 7.57% | 15.6% | 26.87% | — |
ProAssurance Corporation (PRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
ProAssurance Corporation (PRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jun 26, 2026·SEC
Jun 23, 2026·SEC
Jun 2, 2026·SEC
Get notified when PRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ProAssurance Corporation (PRA) stock FAQ — growth, dividends, profitability & financials explained
ProAssurance Corporation (PRA) saw revenue decline by 2.7% over the past year.
Yes, ProAssurance Corporation (PRA) is profitable, generating $65.2M in net income for fiscal year 2025 (4.6% net margin).
ProAssurance Corporation (PRA) has a return on equity (ROE) of 4.0%. This is below average, suggesting room for improvement.
ProAssurance Corporation (PRA) has a combined ratio of 93.4%. A ratio below 100% indicates underwriting profitability.
